In clinical trials in Asians, uveitis was seen in 3% (1/38) in a phase 1b study (KEYNOTE-025) of pembrolizumab in Japanese patients with previously treated PD-L1-positive advanced NSCLC (Nishio et al., 2019). Here, CD274 is linked to non-small cell lung carcinoma.